Akademik Veri Yönetim Sistemi
ACTA MEDICA MEDITERRANEA, sa.6, ss.3269-3272, 2019 (SCI-Expanded)
Introduction: AKT overexpression has shown in some cancer types such as breast, prostate, ovarian and gastric cancer (1, 2, 3). Due to conflicting results reported in recent studies investigating the phosphoinositide-3-kinase-protein kinase (PI3K) signal transduction pathway and lung cancer, we know AKT2 plays a critical role (4). The aim of our study is to investigate whether circulating AKT2 levels have diagnostic, predictive and prognostic role in lung cancer. Materials and methods: We performed enzyme-linked immunosorbent assay (ELISA) to measure and compare AKT2 protein levels in peripheral blood from 74 lung cancer patients (non small cell lung cancer (NSCLC)) and small cell lung cancer (SCLC)) and 40 healthy control group. Results: Serum AKT2 levels were significantly higher in patients with lung cancer (mean: 9.18 +/- 2.64; median 9,6 ng/ml) than the healthy controls (0.52 +/- 0.26; median 0.5 ng/ml) (p=0.00). Area under curve (AUC) value calculated as 0.890 by ROC curve. Increased serum AKT2 concentrations in lung cancer were independent from any of clinicopathological or demographic characteristics. We found no prognostic effect of AKT2 in the whole group, as well as non-metastatic or metastatic subgroups analyzed separately. Discussion and conclusion: To the best of our knowledge, this is the first study to determine diagnostic role of serum AKT2 levels in lung cancer. Although the small sample size and the short follow up time are limitations and may have influenced the results, this study still contributes a significant deal to the literature in that it was carried out with the serum instead of tissue, contained both NSCLC and SCLC of lung cancer and dealt with AKT2 isoform separately We need further studies to elucidate its prognostic roles in lung cancer patients.